Intercalated Gefitinib Plus Chemotherapy Improves DFS in Resected EGFR-Mutant NSCLC Infographic

Firmonertinib 160 mg Demonstrates Efficacy in EGFR-Mutated NSCLC With Leptomeningeal Mets

September 24, 2026

BH-30643 Shows Activity in EGFR C797S+ NSCLC After Resistance to Prior TKI

September 24, 2026

VRN110755 Elicits Responses With Manageable Safety in EGFR C797S+ NSCLC

September 24, 2026

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC Infographic

September 23, 2026